Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000895421-25-000177
Filing Date
2025-02-03
Accepted
2025-02-03 13:09:31
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7832
2 EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT EXHIBIT_NO.99.1.txt EX-99.1 CHARTER 1394
3 EXHIBIT NO. 99.2 ITEM 7 INFORMATION EXHIBIT_NO.99.2.txt EX-99.2 OPIN COUNSEL 685
  Complete submission text file 0000895421-25-000177.txt   11800
Mailing Address 1585 BROADWAY NEW YORK NY 10036
Business Address 1585 BROADWAY NEW YORK NY 10036 212-761-4000
MORGAN STANLEY (Filed by) CIK: 0000895421 (see all company filings)

EIN.: 363145972 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)

Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Subject) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90187 | Film No.: 25581639
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)